PriceTargets.com logo

Chemed - CHE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $574.25
  • Forecasted Upside: 35.28%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$424.50 As of 12/4/2025 04:59 PM ET
▼ -6.33 (-1.47%)

This chart shows the closing price for CHE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chemed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHE

Analyst Price Target is $574.25
▲ +35.28% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Chemed in the last 3 months. The average price target is $574.25, with a high forecast of $595.00 and a low forecast of $550.00. The average price target represents a 35.28% upside from the last price of $424.50.

This chart shows the closing price for CHE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Chemed. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/10/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$589.00 ➝ $572.00
10/30/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/8/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/10/2025Bank of AmericaLower TargetBuy ➝ Buy$610.00 ➝ $595.00
9/2/2025Jefferies Financial GroupUpgradeHold ➝ Buy$490.00 ➝ $550.00
7/31/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$640.00 ➝ $589.00
7/31/2025OppenheimerLower TargetOutperform ➝ Outperform$650.00 ➝ $580.00
7/25/2025Jefferies Financial GroupInitiated CoverageHold$500.00
6/30/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$674.00 ➝ $640.00
6/30/2025Bank of AmericaLower TargetBuy ➝ Buy$708.00 ➝ $650.00
4/28/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$667.00 ➝ $674.00
3/14/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$633.00 ➝ $667.00
11/5/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$697.00 ➝ $633.00
5/21/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$712.00 ➝ $697.00
3/4/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$604.00 ➝ $712.00
2/29/2024OppenheimerBoost TargetOutperform ➝ Outperform$625.00 ➝ $650.00
1/17/2024OppenheimerBoost TargetOutperform ➝ Outperform$590.00 ➝ $625.00
10/30/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$576.00 ➝ $604.00
7/31/2023Royal Bank Of CanadaLower TargetOutperform$610.00 ➝ $576.00
5/1/2023Royal Bank Of CanadaBoost Target$587.00 ➝ $610.00
4/28/2023OppenheimerBoost Target$580.00 ➝ $610.00
2/27/2023Royal Bank Of CanadaBoost TargetOutperform$545.00 ➝ $587.00
11/3/2022Royal Bank Of CanadaBoost TargetOutperform$541.00 ➝ $545.00
8/1/2022Royal Bank Of CanadaLower TargetOutperform$592.00 ➝ $541.00
3/4/2022Royal Bank Of CanadaLower TargetOutperform$609.00 ➝ $579.00
7/29/2021Royal Bank Of CanadaBoost TargetOutperform$604.00 ➝ $609.00
2/25/2021OppenheimerLower TargetOutperform$600.00 ➝ $580.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.35 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 58 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 47 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 28 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2025
  • 27 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
8/6/2025
  • 45 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 38 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 23 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 39 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 39 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Chemed logo
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Read More

Today's Range

Now: $424.50
Low: $421.30
High: $430.00

50 Day Range

MA: $438.72
Low: $424.50
High: $465.48

52 Week Range

Now: $424.50
Low: $408.42
High: $623.60

Volume

126,481 shs

Average Volume

133,993 shs

Market Capitalization

$6.01 billion

P/E Ratio

22.45

Dividend Yield

0.56%

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Chemed?

The following equities research analysts have issued research reports on Chemed in the last twelve months: Bank of America Corporation, Jefferies Financial Group Inc., Oppenheimer Holdings, Inc., Royal Bank Of Canada, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for CHE.

What is the current price target for Chemed?

0 Wall Street analysts have set twelve-month price targets for Chemed in the last year. Their average twelve-month price target is $574.25, suggesting a possible upside of 35.3%. Bank of America Corporation has the highest price target set, predicting CHE will reach $595.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $550.00 for Chemed in the next year.
View the latest price targets for CHE.

What is the current consensus analyst rating for Chemed?

Chemed currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CHE.

What other companies compete with Chemed?

Other companies that are similar to Chemed include Medpace, Labcorp, Quest Diagnostics, DaVita and CorVel. Learn More about companies similar to Chemed.

How do I contact Chemed's investor relations team?

Chemed's physical mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company's listed phone number is (513) 762-6690. The official website for Chemed is www.chemed.com. Learn More about contacing Chemed investor relations.